N@N

iCAD Launches SecondLook Premier in Europe and Canada

^{Published on 2011-02-16 08:35:28 - Market Wire}
 

NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces the availability of its SecondLook^® Premier* computer-aided detection (CAD) technology for digital mammography. SecondLook Premier was developed to provide breast imagers with the most advanced and customizable digital mammography CAD system providing improved cancer detection through increased sensitivity, reduced false positives and robust clinical decision support tools. The technology expands on the SecondLook platform and provides the richest set of clinical decision support tools available in the digital mammography marketplace today. Its CAD metrics provide automated measurements of mammographic characteristics while CAD iNSIGHT provides the rationale for each CAD detection. These tools provide industry leading CAD tissue and lesion characteristics to support the breast imager.

"The SecondLook Premier product has a marked reduction in false positives and improved sensitivity. During the period of the evaluation I noticed fewer marks, notably less vascular marks and more two view positives. The marking logic is much improved"

aBuilding on iCADa™s eight years of commercial experience with cancer detection, tissue analysis and workflow optimization, we are excited to introduce SecondLook Premier to the international healthcare markets. We believe that SecondLook Premier will provide an unmatched level of cancer detection in addition to next generation tissue analysis tools,a said Ken Ferry, President and CEO of iCAD. aThe new SecondLook Premier, which is now available in Europe and Canada, debuted with great excitement at the RSNA meeting in December and we are confident that it will provide new and existing customers with a superior level of cancer detection that spans a wider range of reader preferences as they seek to detect more breast cancer at an earlier stage.a

SecondLook Premier is optimized for leading digital mammography systems, GE Healthcare, and Siemens Medical Systems. It offers improved detection of soft tissue densities and calcifications, increased lesion marking in two views, and up to a 50% reduction in false negatives. The algorithm also offers improved false positive performance, with reduced marking of vascular and other benign calcifications. It allows for three operating points to match breast imagersa™ reading preferences. These operating points span a widerrange of readers' preferences and can beindependently set for soft tissue densities and calcifications. In addition, iCADa™s SecondLook Digital provides the most powerful flexible DICOM connectivity solution enabling universal compatibility with leading PACS and Review Workstations.

aThe SecondLook Premier product has a marked reduction in false positives and improved sensitivity. During the period of the evaluation I noticed fewer marks, notably less vascular marks and more two view positives. The marking logic is much improved,a said Dr. Bohm-Velez, Weinstein Imaging, Pittsburgh, PA. aThe use of the breast density assessment system helps us with standardization and minimizes inter reader variability.The use of CAD metrics enables me to understand the CAD markings and what triggered its decision.a

*Investigational Device. Limited by Federal Law to Investigational Use Only. Available Outside US.

About iCAD

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent® eBxa" electronic brachytherapy system (eBx). Axxent uses non-radioactive miniaturized X-ray tube technology and is FDA-cleared for treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). For more information, call (877) iCADnow or visit [ www.icadmed.com ].

**NOTE TO EDITORS, IMAGES AVAILABLE

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Companya™s filings with the Securities and Exchange Commission. The words abelievea, ademonstratea, aintenda, aexpecta, aestimatea, aanticipatea, alikelya, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.